Proacta’s lead compound, PR104, has entered Phase 2 clinical trials. This is an exciting milestone for the company. After showing signs of activity in early Phase 1 clinical trials – which establish how much of the drug can safely be administered, PR104 is now being evaluated in Phase 2 trials to test its efficacy for both liver cancer and lung http://www.phpaide.com/?langue=fr&id=5 cancer. These trials are being conducted in New Zealand, Asia, Canada, and the US. Results should be available by mid-2010.
No 8 Ventures co-led the Series A investment in Proacta five years ago, basing its investment decision on the increasing evidence that hypoxia (shortage of oxygen) is important in solid tumours and the world-leading intellectual property in this area developed by scientists at the University of Auckland and Stanford University, which formed the basis for the company.
For more, see www.proacta.com